-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The ongoing COVID-19 pandemic requires accelerated testing of candidate vaccines
COVID-19 immunity
In the first phase, healthy people aged 18-80 were included in the study.
Screening
The results showed that in the first stage, 192 participants (average age 53-7 years [SD 15-6]) were randomly assigned to receive the vaccine (2μg[n=24], 4μg[n=24], or 8μg[n =24], two age groups [18-59 years old and ≥60 years old]) or placebo (n=24)
In Phase 2, 448 participants (mean age 41.
In summary, the SARS-CoV-2 inactivated vaccine BBIBP-CorV is safe and well tolerated in all doses tested in both age groups
Original source:
Shengli Xia, Yuntao Zhang, et al.
Safety and immunogenicity of an inactivated SARS- CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
in this message